Dermatology quality of life and psychological morbidity in patients with chronic dermatophytosis

Authors

  • Anushree LS Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka, India
  • Anupama YG Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka, India.
  • Praveena C Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka
  • Dadapeer HJ Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka

Keywords:

Chronic dermatophytosis, Dermatology Life Quality Index, General Health Questionnaire

Abstract

Objective Dermatophytosis is defined as chronic when patients with dermatophytosis experience the symptoms for longer than 6 months to 1 year with or without recurrence after receiving sufficent treatment. The aim of our study is to assess the quality of life and psychological burden in patients with chronic dermatophytosis.   Methods  A cross sectional descriptive study was conducted among 69 patients diagnosed with chronic dermatophytosis for a period of 4 months (Jan-April 2022). A preformed structured proforma was used, which included demographic data, duration, type, site, body surface area, severity of pruritus, Dermatology Life Quality Index (DLQI) and General Health Questionnaire (GHQ-12).   Results The mean age group was 38.6±11.7 with males (43.48%) and females (56.52%). The most common sites affected were thigh folds and trunk 24.64% each and itching being severe in 62.32% patients. The main domains affected by the DLQI questionnaire were symptoms and feelings followed by work and school with the mean total DLQI score of 12.7±7.3 (range 0-30). The GHQ score was more than 12 in 88.4% patients, with the mean total GHQ-12 score of 13.6±2.4 (range 0-12), indicating significant psychological influence of the disease. The correlation coefficient between GHQ-12 and DLQI was r=0.5, P<0.05, indicating a positive correlation between the two.   Conclusion Chronic dermatophytosis had a significant impact on psychosocial life of patient. Therefore it is important to treat and counsel patients regarding preventive measures, adherence to treatment and also these questionnaires can be used as tool of prognostic significance while following up patients in future.  

Author Biographies

Anupama YG, Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka, India.

Associate professor

Praveena C, Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka

Postgraduate student

Dadapeer HJ, Department of Dermatology, Venerology and Leprosy, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka

HOD and Professor

References

Rajagopalan M, Inamadar A, Mittal A, et al. Expert Consensus of the Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18:6.

Naglot A, Shrimali DD, Nath BK, Gogoi HK, Veer V, Chander J, Tewari R. Recent trends of dermatophytosis in Northeast India (Assam) and interpretation with published studies. Int J Curr Microbiol App Sci. 2015;4(11):111-20.

Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive?. Indian Dermatol Online J. 2016;7:73-6.

Brigida S, Muthiah N. Pediatric Sedation: Prevalence of Tinea Corporis and Tinea Cruris in Outpatient Department of Dermatology Unit of a Tertiary Care Hospital. J of Pharmacol Clin Res. 2017; 3(1): 555602.

Verma S, Madhu R. The Great Indian Epidemic of Superficial Dermatophytosis: An Appraisal. Indian J Dermatol. 2017;62(3):227-36.

Narang T, Bhattacharjee R, Singh S, et al. Quality of life and psychological morbidity in patients with superficial cutaneous dermatophytosis. Mycoses.2019;62:680–5.

Das A, Fatima F, Sil A, Podder I, Jafferany M. Therapeutic management of psychological morbidity and impaired quality of life in patients with persistent dermatophytoses. Dermatol Ther. 2020;33(6):e14124.

Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659-64.

Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, Rutter C. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med. 1997;27(1):191-7.

Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: A comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997-1035.

Doshi B, Sajjan V, Manjunathswamy BS, Bindagi AP. Cross-sectional study on assessing quality of life of patients diagnosed with superficial dermatophytosis in South-West India. Indian J Health Sci Biomed Res. 2020;13:160-4.

Bashir S, Hassan I, Wani RT. Influence of dermatophytosis on quality of life: a cross sectional study from Kashmir Valley in North India. Int J Community Med Public Health. 2020;7:1711-6.

Shukla P, Verma P, Suvirya S, Pathania S, Kapoor D. Cutaneous dermatophytosis: A problem deeper than we perceive–A cross sectional prospective study on quality of life in 385 patients. Clini Epidemiol Glob Health. 2022;31:101115.

Rajashekar TS, Nandigonnanavar S, Kuppuswamy SK, Madhavi GS. Dermatology life quality index in patients with persisting and recurrent dermatophytoses. Int J Res Dermatol. 2019;5:139-43.

Patro N, Panda M, Jena AK. The menace of superficial dermatophytosis on the quality of life of patients attending referral hospital in Eastern India: A cross-sectional observational study. Indian Dermatol Online J. 2019;10:262-6.

Varshney AP, Gahalaut P, Pardal PK, Mishra N, Rastogi MK, Thapa M. Quality of life in patients with chronic dermatophytosis. Nep J Dermatol Venereol Leprol. 2020;18(1):44-51.

Downloads

Published

2023-03-05

How to Cite

1.
Anushree LS, Anupama YG, Praveena C, Dadapeer HJ. Dermatology quality of life and psychological morbidity in patients with chronic dermatophytosis. J Pak Assoc Dermatol [Internet]. 2023Mar.5 [cited 2024Jun.17];33(1):84-90. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2036

Issue

Section

Original Articles